Amgen Inc. (AMGN) Announces EC’s Grant of Marketing Authorization for IMDYLLTRA®

Amgen Inc. (NASDAQ:AMGN) is one of the best cheap stocks to buy for beginners. Amgen Inc. (NASDAQ:AMGN) announced on June 1 that the European Commission granted marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for the treatment of adults with extensive-stage small cell lung cancer who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy. Management reported that the approval was based on results from DeLLphi-304, which is the first global Phase 3 trial to exhibit a significant survival benefit over chemotherapy in this setting.

Jean-Charles Soria, senior vice president of Oncology at Amgen Inc. (NASDAQ:AMGN), stated that IMDYLLTRA is the first and only T-cell engager therapy approved to treat small cell lung cancer, and the approval by the European Commission marks a critical step forward for patients in Europe.

Amgen Inc. (NASDAQ:AMGN) further reported that DeLLphi-304, the global Phase 3 clinical trial, showed that “IMDYLLTRA reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard of care (SOC) chemotherapy as a treatment for patients with ES-SCLC who progressed on or after one line of platinum-based chemotherapy”.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.